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Targeting LGR5 in Colorectal Cancer: therapeutic gold or too
plastic?
RG Morgan 1,2, E Mortensson 1 and AC Williams1
Leucine-rich repeat-containing G-protein coupled receptor (LGR5 or GPR49) potentiates canonical Wnt/β-catenin signalling and is a
marker of normal stem cells in several tissues, including the intestine. Consistent with stem cell potential, single isolated LGR5+ cells
from the gut generate self-organising crypt/villus structures in vitro termed organoids or ‘mini-guts’, which accurately model the
parent tissue. The well characterised deregulation of Wnt/β-catenin signalling that occurs during the adenoma-carcinoma sequence
in colorectal cancer (CRC) renders LGR5 an interesting therapeutic target. Furthermore, recent studies demonstrating that CRC
tumours contain LGR5+ subsets and retain a degree of normal tissue architecture has heightened translational interest. Such
reports fuel hope that speciﬁc subpopulations or molecules within a tumour may be therapeutically targeted to prevent relapse
and induce long-term remissions. Despite these observations, many studies within this ﬁeld have produced conﬂicting and
confusing results with no clear consensus on the therapeutic value of LGR5. This review will recap the various oncogenic and
tumour suppressive roles that have been described for the LGR5 molecule in CRC. It will further highlight recent studies indicating
the plasticity or redundancy of LGR5+ cells in intestinal cancer progression and assess the overall merit of therapeutically targeting
LGR5 in CRC.
British Journal of Cancer (2018) 118:1410–1418; https://doi.org/10.1038/s41416-018-0118-6
INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy
diagnosed globally and the fourth leading cause of cancer-related
death worldwide, with its burden predicted to increase by 60% by
2030.1 CRC progresses through a well-deﬁned adenoma-carci-
noma sequence,2 whereby the stepwise acquisition of well-
characterised genetic mutations (e.g. APC, KRAS, TP53) drives
intestinal crypt dysplasia, followed by the development of
colorectal tumours. Although detection and treatment protocols
have improved markedly, most patients who present with a
late-stage cancer will succumb to their disease through relapse. A
widely accepted cause of CRC relapse is the failure of
current therapies to eradicate cancer stem cell (CSC) subpopula-
tions within a tumour. CSCs express a variety of markers
including CD133,34 CD44, CD166,5 ALDH,6 EphB2 and leucine-
rich repeat-containing G-protein coupled receptor 5 (LGR5).7
These CSCs are able to survive therapeutic insult and re-establish
tumour growth following therapeutic intervention, and there is
therefore an urgent medical need for novel, non-toxic targeted
cancer therapies that can induce durable clinical remissions.
A fundamental event for early CRC progression is deregulation
of the Wnt/β-catenin signalling pathway, which is constitutively
activated through genetic mutations to APC or, more rarely, β-
catenin.8,9 Under normal conditions, the absence of a Wnt ligand
leads to constitutive phosphorylation of the central mediator, β-
catenin, through a destruction complex consisting of GSK3β, CK1,
Axin and APC. This primes β-catenin for subsequent degradation
by the proteasome, leaving Wnt target genes in a repressed
state. Upon Wnt ligand binding to the Wnt receptors Frizzled and
LRP5/6, phosphorylated β-catenin saturates the destruction
complex but cannot be ubiquitinated or degraded.10 The resulting
cytosolic accumulation of β-catenin leads to its nuclear transloca-
tion where it binds the TCF/LEF family of transcription factors
and activates proto-oncogenic Wnt target genes, such as c-myc,
cyclinD1 and survivin.
LGR5 (also known as GPR49) is a seven-transmembrane protein
of the class A Rhodopsin-like family of GPCRs. Within this GPCR
superfamily LGR5 falls within the orphan subgroup of glycoprotein
receptors (including LGR4 and LGR6), which are characterised
by uniquely large ectodomains containing 17 leucine-rich repeat
sequences.11 Despite its historic classiﬁcation as an ‘orphan’
receptor, LGR5 now has a well-established ligand in R-Spondin
(RSPO), which, when bound, acts in cooperation with Wnt
receptors (Frizzled and LRP5/6) to potentiate Wnt/β-catenin
signalling.12–14 The LGR5/RSPO complex is able to promote Wnt
signalling through the neutralisation of two transmembrane E3
ligases, RNF43 and ZNRF3 (Fig. 1).15 These enzymes are Wnt
targets that remove Wnt receptors from the cell surface, thus
serving as part of a negative feedback loop to regulate Wnt
signalling output.
LGR5 is also a target gene of Wnt16 and marks normal stem cells
in multiple tissues, including the small and large intestine.17 The
expression of LGR5 during normal intestinal homeostasis is
restricted to the stem cell compartment located at the crypt
base. This LGR5 expression is lost from stem cell progeny as
they migrate upwards through the transit amplifying zone and
undergo differentiation.16 In support of this, single isolated LGR5+
cells from the gut form self-organising crypt/villus structures
www.nature.com/bjc
Received: 20 November 2017 Revised: 2 April 2018 Accepted: 5 April 2018
Published online: 30 May 2018
1School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK and 2School of Life Sciences, University of Sussex,
Falmer, Brighton BN1 9QG, UK
Correspondence: RG Morgan (rhys.morgan@sussex.ac.uk)
© The Author(s) 2018 Published by Springer Nature on behalf of Cancer Research UK
termed organoids, which are able to recapitulate the full
repertoire of differentiated epithelial lineages present in the
intestine.18 Further studies have shown that stem cell/progenitor
hierarchies are maintained in CRC tissue, and that LGR5 acts as a
CSC marker.7,19–21 This has elevated translational interest in LGR5,
since therapeutic targeting of the molecule, or the tumour
subpopulations it marks, may represent an efﬁcacious strategy
for eradicating tumours and their relapse clones. However, it is
over 10 years since the initial characterisation of LGR5 as an
intestinal stem cell marker,16 and LGR5−targeted therapies have
not yet reached the clinic for CRC. Furthermore, the associated
literature contains conﬂicting and contradictory results (Table 1).
This review will discuss the various oncogenic and tumour
suppressor roles previously ascribed to LGR5 in CRC. We will also
recap more recent data highlighting the plasticity and redundancy
of LGR5+ cells during tumour progression (Table 2), and consider
the overall therapeutic merit of targeting LGR5 in CRC.
ONCOGENIC ROLES FOR LGR5 IN CRC
Given its well documented role in potentiating Wnt/β-catenin
signalling (and the wider involvement of this pathway in CRC
pathology), it is not surprising that many reports have indicated
a pro-oncogenic role for LGR5 in CRC. These include studies
that have examined LGR5 expression in CRC patient tissue, its
prognostic value, and its functional signiﬁcance in experimental
models.
LGR5 is overexpressed in CRC
The majority of the observational studies in primary clinical
tissue have suggested a positive role for LGR5 expression in
CRC progression (reviewed elsewhere22). Many studies have
noted a higher expression of LGR5 in CRC cells, relative to the
adjacent normal tissue.23–34 Furthermore, a number of studies
have highlighted increased LGR5 expression at the invasive front
of tumours,24,26,29–32,35 and distant metastases.24,26,27,30,31,36,37
Caution must be taken when inferring functional signiﬁcance for
LGR5 expression at the invasive front of tumours, since this
localisation is also shared with nuclear β-catenin.38–40 Given that
LGR5 is itself a Wnt target gene this expression pattern may simply
mark Wnt signalling activity, rather than a deﬁned functional
role within this setting. In support of this, a study by Baker and
colleagues noted heterogeneous localisation of LGR5 expression
between the serrated (~ 10–20% cases, non-APC mutant) and
conventional (~ 80–90% cases, APC mutant) pathways of CRC,
which may reﬂect the variable Wnt signalling status of these
pathologies.32
LGR5 expression predicts adverse prognosis
LGR5 has been assessed as a prognostic indicator or predictor of
response to therapy in CRC; most studies indicate that LGR5
expression is associated with poor clinical outcome. In elegant
experiments, Merlos-Suarez et al used mouse small intestine to
generate gene expression signatures for normal intestinal stem
cells, based on expression of LGR5 (and EphB2). When these
independent gene signatures were examined in a cohort of 340
CRC patients they were found to strongly associate with disease
relapse, metastatic progression, and poorly differentiated tumour
types.7 Two meta-analyses, one by Chen et al (covering seven
studies, 1883 patients) and the other by Jiang et al (covering
12 studies, 2600 patients), associated high LGR5 expression with
shorter overall survival (OS) and disease free survival (DFS).41,42
These analyses included studies by Wu,24 Hsu27 and He et al,26
which all used immunohistochemical measurement of LGR5
expression in primary patient samples to link higher expression
with reduced overall survival in cohorts of 192, 296, and 53 CRC
patients, respectively. Takahashi et al, used qRT-PCR to assess
the LGR5 level and arrived at the same conclusion.29 The study by
Hsu and colleagues analysed LGR5 expression in the context
of treatment response and reported patients with lower LGR5
expression had a better response to 5FU-based therapy.27
Similarly, Stanisavljević et al noted a longer time to tumour
recurrence (TTR) from patients with low LGR5 mRNA expression in
response to ﬂuoropyrimidine-based adjuvant chemotherapy.43 A
further study by the Lenz group examined the clinical relevance of
germline LGR5 polymorphisms. The authors identiﬁed a single
nucleotide polymorphism (SNP) in the LGR5 gene (rs17109924)
that was signiﬁcantly associated with reduced TTR.44 In contrast,
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Fig. 1 LGR5 promotes Wnt/β-catenin signalling. LGR5 has a well-deﬁned function in the promotion of Wnt/β-catenin signalling in normal
intestinal stem cells. Without RSPO bound to LGR5, Wnt signalling is kept low through the action of transmembrane E3 ligases RNF43/ZNRF3,
which internalise and degrade the Wnt receptors Frizzled and LRP5/6. This leads to downstream β-catenin degradation and subsequent
repression of Wnt target genes. The binding of RSPO to LGR5 sustains Wnt signalling by neutralising the RNF43/ZNF3 ligases, which can no
longer remove Wnt receptors from the cell membrane. FZD and LRP5/6 are free to bind Wnt ligands leading to stabilised β-catenin and
downstream activation of Wnt target genes such as c-MYC, CyclinD1 and Axin2
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an allelic variant of the same SNP (rs17109924) predicts better
response to 5FU-based adjuvant chemotherapy.45 However,
neither study demonstrated how the SNP impacted LGR5
expression, which is crucial given that primary colorectal
carcinomas harbouring variant LGR5 genotypes can exhibit
signiﬁcantly lower LGR5 protein expression.37
Pro-oncogenic functional studies
To complement the correlative studies highlighted above, many
groups have attempted to characterise LGR5 function in CRC cells
through genetic manipulation of the LGR5 receptor in human CRC
cell lines; much of this data has indicated a pro-tumourigenic
role for LGR5. Hirsch et al used siRNA to show that repression of
LGR5 in SW480 and HT29 cells resulted in reduced proliferation,
migration and colony formation, both in vitro and when
xenotransplanted.46 These effects were particularly marked in
the detached spheroid fraction of SW480 cells, which are enriched
for stemcell associated genes (including LGR5). Lin and colleagues
reported reduced cell proliferation and lower expression of APC
and β-catenin upon treatment of HT29 cells with LGR5 siRNA.34 An
LGR5 siRNA approach was also adopted by Hsu et al, who
observed suppressed cell growth and colony formation, alongside
increased apoptosis on LGR5 knockdown.47 Furthermore, work
by Chen and co-workers, exclusively in the HT29 cell line,
showed that LGR5 siRNA had multiple tumour suppressive
effects including: inhibition of cell proliferation, reduced second-
ary tumour sphere formation, induction of apoptosis, enhanced
chemosensitivity, reduced invasive capacity and decreased
expression of stem cell markers CD133 and CD44.48 Another
study by Hsu et al involved both transient LGR5 knockdown
(LoVo and HT29) and overexpression (HCT116 and HT29) in CRC
cell lines.27 Whereas treatment with LGR5 siRNA repressed cell
proliferation, inhibited colony formation, enhanced apoptosis and
sensitised cells to chemotherapy, LGR5 induction increased both
cell proliferation and chemoresistance.
Moving from cell lines into primary CRC patient samples, the
Medema group demonstrated that the LGR5+ fraction of tumours
exhibited enhanced TCF/LEF activity (a measure of Wnt signalling
output) and greater clonogenic capacity (both in vitro and in vivo),
relative to the LGR5− fraction.49 Interestingly, the LGR5− fraction
retained some clonogenic growth in vitro, and reacquired LGR5
positivity a week post sorting, suggesting a level of dependence
on LGR5 for proliferation. In the same study, LS174T cells stably
overexpressing LGR5 exhibited enhanced clonogenicity, whereas
shRNA-mediated knockdown of LGR5 in primary CSC populations
completely abolished clonogenic capacity. Finally, many signalling
pathways commonly implicated in CRC are known to target LGR5
expression. LGR5 is a well-established target of Wnt/β-catenin
signalling,16 but evidence from our laboratory has also shown
that the PGE2 and EGF signalling pathways can alter LGR5
expression, which impacts the proliferation/survival capacity of
human colorectal adenomas.50,51 Collectively, the overexpression
of LGR5 in primary tissue, association with poor patient prognosis,
and the pro-tumourigenic activity of LGR5 in in vitro functional
studies would indicate a pro-oncogenic role for LGR5 in colorectal
tumourigenesis.
Table 1. Summary of the various oncogenic and tumour suppressor roles previously ascribed for LGR5 in CRC
Main ﬁndings Models and studies
Oncogenic roles for LGR5 in CRC
LGR5 is overexpressed in CRC Primary human/mouse CRC and adenoma cells23–37
LGR5 expression predicts adverse prognosis Primary human CRC;7,24,26,27,29 Meta-analyses41,42
LGR5 knockdown reduces proliferation, growth, migration, clonogenicity, invasion,
PGE2-mediated survival and increases apoptosis, chemosensitivity
Human CRC cell lines;34,46–48 Human adenoma cell lines50
LGR5 overexpression increases proliferation and chemo-resistance Human CRC cell lines27
LGR5 positivity confers greater clonogenic capacity Human CRC cell lines and primary human CRC tumours49
Tumour suppressor roles for LGR5 in CRC
Loss of LGR5 expression during CRC progression Human CRC cell lines and primary CRC tumours;50,53 Primary
human CRC cells52
LGR5 expression predicts favourable prognosis Primary human CRC52
LGR5 suppresses Wnt signalling Mouse small intestine;54,55 Human CRC cell lines;56 Human CRC
cell lines and primary human CRC tumours57,58
LGR5 knockdown increases invasion, growth, proliferation (including EGF-
mediated) and tumourigenicity
Human CRC cell lines;56 Human adenoma cell lines51
LGR5 overexpression reduces proliferation CRC cell lines;56 Human CRC cell lines and primary human CRC
tumours57,58
Table 2. Summary of the various studies demonstrating plasticity of LGR5+ cells in both the normal gut and CRC
Main ﬁnding Models and studies
Normal gut homeostasis upon loss of LGR5+ cells Mouse intestine/organoids60–64
LGR5+ pool contains heterogeneous subpopulations Mouse intestine in vivo/organoids65,66
LGR5 expression has no prognostic value Primary human CRC tumours31,68
LGR5− cells can sustain tumour growth (LGR5+ cells required for metastatic
progression)
Human CRC organoids;21 Mouse organoids69
APC deletion in LGR5− cells is tumourigenic Mouse intestine/organoids64
LGR5+ cells interconvert with LGR5− cells for drug resistance Human cell lines derived from xenografted primary CRCs70
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TUMOUR SUPPRESSOR ROLES FOR LGR5 IN CRC
Studies of LGR5 expression in primary tumour samples and of
LGR5 function (including the impact on Wnt signalling) have also
suggested a potential tumour suppressive function in CRC
development.
Loss of LGR5 expression during CRC progression
Contrary to the studies discussed above, reports have also
suggested that loss of LGR5 expression is observed during CRC
progression. De Sousa and colleagues performed gene set
enrichment analysis in primary CRC tumours derived from good
vs. poor prognosis patients.52 Surprisingly, high expression of Wnt
target genes (including LGR5) was associated with a good
prognosis, independent of CSC content or nuclear β-catenin level.
Wnt target genes were downregulated during CRC progression
and several, including LGR5, were found to be methylated in both
CRC cell lines and primary tumours. Interestingly, re-expression of
these genes through the demethylating agent 5-Aza lowered the
clonogenicity of cell lines and primary isolated colon CSCs, and
supressed tumour growth upon xenografting. On a similar theme,
Su et al used methylation-speciﬁc PCR to analyse the status of the
LGR5 promoter in six CRC cell lines and 169 primary CRC
samples.53 LGR5 promoter methylation was completely absent in
normal colonic tissue; however, varying degrees of methylation
were observed in half of the CRC cell lines examined (HCT116,
complete methylation; SW480 and SW620, partial methylation)
and 40% of the primary tumour samples, where it correlated with
higher tumour grade. Interestingly, any requirement for a
reduction in LGR5 expression during the adenoma-carcinoma
transition ﬁts with the LGR5 protein expression pattern we have
observed from our panel of human CRC cell lines. High LGR5
protein expression was present in all adenoma cell lines (AA/C1,
AN/C1, BH/C1, RG/C2) but absent or low in the majority of
carcinoma cell lines (DLD-1, HCA7, HCT116, HCT-15, HT29, LS174T,
RKO). LGR5 expression returned to high levels in the metastatic
cell lines (LoVo and SW620) suggesting that reacquisition of LGR5
expression could be an important event in the metastatic
progression of CRC.50
Negative regulation of Wnt signalling by LGR5
The ﬁrst indication that LGR5 could have potential tumour
suppressive effects in the gut came from studies showing a
negative inﬂuence on Wnt signalling. Garcia et al found LGR5 had
little impact on Wnt signalling in the developing small intestine,
since LGR5-null mice exhibited no alterations to cell proliferation,
migration, or epithelial differentiation in the gut.54 Further
molecular analyses within these LGR5−/− animals actually
revealed Wnt activation, with signiﬁcant upregulation of many
Wnt target genes including Axin2, Ascl2 and CD44. These ﬁndings
suggested that LGR5 has a suppressive inﬂuence over Wnt gene
expression. Similarly, the Tchorz group also reported increased
Axin2 mRNA levels in LGR5 knockout mice.55 Furthermore, Walker
et al created LGR5-silenced and overexpressing LIM1899 and
LIM1215 colorectal cell lines, and showed that LGR5 negatively
regulated a subset of established Wnt target genes including LEF1,
Frz7 and WISP1.56
A more recent study by Wu and colleagues identiﬁed RSPO2 as
downregulated in human CRC cell lines and primary tumours,
relative to normal colonic mucosa, due to promoter hypermethy-
lation.57 RSPO2 overexpression had an inhibitory effect on CRC cell
line growth and Wnt signalling output, whilst increasing LGR5
expression. Silencing of LGR5 reversed these effects by restoring
the LRP6 phosphorylation and β-catenin accumulation previously
inhibited by RSPO2. Conversely, in HEK293 cells, RSPO2 stimulated
Wnt signalling, LRP6 phosphorylation, and β-catenin accumula-
tion, which was reversed by stable LGR5 overexpression. Clearly,
context is important since transfection of either RSPO2 or LGR5
alone in HEK293 was sufﬁcient to activate the β-catenin reporter,
whereas only the co-transfection of both LGR5 and RSPO2
resulted in supressed Wnt reporter activity. The authors showed
that this was achieved through RSPO2 interaction with LGR5 and
subsequent membrane stabilisation of the Wnt negative regulator
ZNRF3. Finally, observations in clinical CRC tissue by Osawa and
colleagues correlated Wnt pathway output with the expression of
LGR5 isoforms. Three isoforms were frequently observed that
were deﬁcient in exon 5 (LGR5Δ5), exons 5–8 (LGR5Δ5–8), or exon
8 (LGR5Δ8), in addition to expression of the full-length protein
(LGR5FL).58 Cells overexpressing LGR5FL contained less phos-
phorylated LRP6 and exhibited reduced Wnt signalling output
(determined by TOP-ﬂash assay) compared with cells dominated
by LGR5 splice variants.
LGR5 inhibits the proliferation of CRC cells
Some functional studies have indicated that the LGR5 molecule
could have a tumour suppressive role in CRC by limiting cell
proliferation. In support of this, silencing LGR5 through both shRNA
and siRNA approaches in LIM1899 and LIM1215 CRC cell lines
increased invasion, anchorage-independent growth, and enhanced
tumourigenicity in xenograft experiments.56 Conversely, overexpres-
sion of LGR5 resulted in augmented cell adhesion, reduced
clonogenicity, and attenuated tumourigenicity. Further support for
a tumour limiting role was provided by the Wu study which
reported that LGR5 overexpression alone (or in combination with
RSPO2) was sufﬁcient to inhibit HT29 cell proliferation.57 This result
would appear to be at odds with the study mentioned previously,
where LGR5 overexpression promoted HT29 cell proliferation.27 This
difference may have arisen through the contrasting LGR5 over-
expression systems used between the studies, with the Hsu study
employing transient LGR5 overexpression, and the Wu study
adopting stable LGR5 overexpression.
Examination of primary CRC specimens within the Osawa study
showed that the LGR5Δ5, LGR5Δ5–8, or LGR5Δ8 splice variants
appeared during cell cycle progression, whereas LGR5FL was only
expressed during cell cycle arrest. Cells expressing LGR5FL
therefore had less proliferative ability than cells expressing
LGR5 splice variants, and were negative for the Ki-67 proliferation
marker.58 Interestingly, the presence of LGR5FL made HT29 cells
more chemoresistant, and the proportion of LGR5FL-positive cells
in clinical samples was enriched post-chemotherapy, suggesting a
positive role for LGR5 in survival and drug resistance. Indeed, our
most recent study demonstrated that LGR5 silencing signiﬁcantly
enhanced the sensitivity of human adenoma cells to the
epidermal growth factor receptor (EGFR) inhibitor geﬁtinib.51 In
this study, LGR5 mRNA and protein expression was suppressed
during EGF-mediated proliferation of adenoma cells. Taken
together, such ﬁndings indicate that LGR5 expression may play
a key role in mediating the survival and/or proliferative responses
of tumours during malignant transformation.
PLASTICITY OF LGR5+ CELLS IN THE NORMAL GUT AND CRC
The conﬂicting reports of the pro-oncogenic and tumour suppres-
sive functions of LGR5 in CRC may originate from the inherent
plasticity of normal stem cells and CSCs. A host of recent in vivo
studies have nicely demonstrated the ability of LGR5- and LGR5+
cells to freely interconvert during both normal gut homeostasis and
CRC progression (recently reviewed elsewhere.59)
LGR5+ cell plasticity in the normal intestine
In the normal gut, use of a human diptheria toxin receptor (DTR)
gene system knocked into the LGR5 locus has demonstrated no
perturbation in epithelial homeostasis upon LGR5 loss.60,61 Using
this system, DTR is expressed solely in LGR5+ cells so that upon DT
administration, speciﬁc ablation of cells expressing LGR5 occurs. In
one of these studies, the Bmi1-expressing compartment (repre-
senting a reserve stem pool residing just outside the crypt base)
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expanded and regenerated LGR5 expressing progeny, indicative
of a stem cell hierarchy.61 Subsequent reports, however, have
shown that this regeneration capacity is not restricted to the
stem cell compartment, since more differentiated cell types,
including enterocytes,62 Dll1+ secretory cells,63 and KRT19+ cells,64
are capable of de-differentiation and crypt regeneration upon
intestinal damage or LGR5+ cell ablation.
There is further heterogeneity even within the LGR5-expressing
pool itself. Barriga and colleagues recently demonstrated that
the RNA-binding protein Mex3a is a marker of slowly cycling
normal LGR5+ cells with low proliferative capacity, that potentially
survive chemotherapy/radiation and replenish damaged epithe-
lium. Conversely, the Mex3aneg/low pool of rapidly cycling LGR5+
cells were inherently more chemosensitive.65 Similarly, the Winton
group have shown that a quiescent LGR5+ subgroup exists (in
addition to the rapidly cycling subset) that possesses a
differentiated secretory signature and is capable of extensive
proliferation upon intestinal injury.66 These studies therefore
suggest that LGR5 function could vary considerably depending on
which cell type it is expressed in, and could be functionally
dispensable altogether given the ability of LGR5− cells to
compensate and regenerate intestinal epithelium.
Plasticity of LGR5+ CSCs
Given recent ﬁndings that a degree of normal clonal architecture
is retained in CRCs,21,67 it is unsurprising that LGR5 plasticity has
also been observed in tumours. This may help to explain why
LGR5 expression has previously been linked with no prognostic
value.31,68 Using their CRC tumour organoid library, the Sato group
recently demonstrated that CRC organoids (CCO) have preserved
hierarchical heterogeneity, as evidenced by inversely correlated
LGR5 and KRT20 expression (marking stemness and differentia-
tion, respectively).21 Using elegant lineage tracing experiments,
they showed that LGR5+ CRC cells could form both LGR5+
daughters (KRT20−) and LGR5− daughters that acquired KRT20
expression. This indicated that these cells had both self-renewal
and differentiation capacity, similar to their normal counterparts.
LGR5+ cell ablation in CCOs (through an inducible CRISPR/
Cas9 system) resulted in apoptosis and tumour regression;
however, the LGR5−KRT20+ fraction of CCOs exhibited prolifera-
tion competency and could replenish tumour growth through the
regeneration of LGR5 expressing cells.
Similar observations were made by Melo et al, who generated
mouse-derived intestinal tumour organoids mimicking the
sequential acquisition of mutations that occur during human
CRC progression (APC, Kras, Trp53, Smad4).69 Using this model,
limiting-dilution transplants of FACS-sorted tumour cells showed
that tumour-initiating capacity was enriched in the LGR5+ tumour-
cell fractions; however, LGR5− cells could also regenerate tumours
that subsequently contained LGR5+ sub-populations. Upon
ablation of LGR5+ cells from these organoids using the DTR
system, tumours regressed but were not eradicated owing to the
presence of proliferating LGR5− cells, which could reform LGR5+
CSCs. The LGR5− fraction was not functionally equivalent to
LGR5+ CSCs because of their inferior capacity to drive tumour
growth, and LGR5 positivity was ultimately necessary for meta-
static progression of CRC. The same group also demonstrated that
the LGR5 protein may even be dispensable for CRC initiation,
given the plasticity of the cell of origin in CRC. Whereas previous
reports had suggested that tumourigenesis occurred in LGR5+
cells at the crypt base,19 the study by Metcalfe et al found that
crypt hyperplasia was unabated upon APC loss (a major driver of
CRC) in LGR5+-depleted mouse small intestines. Rapidly cycling
Ki-67+ cells were maintained in LGR5−depleted hyperplastic
crypts, implying that LGR5− populations could compensate and
maintain the proliferative drive.60
Along similar lines, Asfaha and colleagues used genetic fate
mapping and lineage tracing to characterise two distinct stem cell
pools in the mouse intestinal epithelium; the rapidly cycling and
radiosensitive LGR5+ pool at the colonic crypt base, and a slower
dividing, long-lived, radioresistant LGR5−KRT19+ fraction outside
the crypt zone (capable of regenerating LGR5+ crypt base
columnar cells).64 Using targeted APC deletion in the KRT19+
fraction they were able to show this pool could also serve as the
initiating pool in intestinal tumourigenesis distinct from the LGR5+
population – a key sign of plasticity.
The modulation of LGR5 expression by CSCs could also be
important for mediating drug resistance. Kobayashi et al gener-
ated cell lines in vitro from primary xenografted CRC tumour
samples and found that LGR5+-sorted cells more efﬁciently
formed colonies in Matrigel and tumours in vivo, compared with
LGR5− cells.70 However, following exposure to drugs such as
irinotecan, 5FU, or oxaliplatin, LGR5+ cells converted to drug-
resistant LGR5− cells with reduced proliferative capacity. Further
analysis of these cells revealed that they retained expression of
multiple stem cell markers including CD133, CD44, and CD166, but
with selectively reduced LGR5 expression. Upon removal of the
drugs and reseeding of cells, LGR5 expression was reacquired and
proliferative potential restored.
Collectively, these studies suggest that, similar to normal gut
homeostasis, there are stages of tumour growth where the LGR5
molecule is functionally redundant. However, the ability of LGR5−
CRC cells to rapidly reacquire LGR5 expression implies there are
speciﬁc phases of tumour growth where LGR5 is important, which
is evident during metastatic progression and drug/radiation
exposure.
OTHER FACTORS AFFECTING LGR5 FUNCTION IN CRC
The difﬁculty in assigning a deﬁnitive role for LGR5 in CRC may arise
from a number of confounding variables including the alternative
functions of Wnt receptors, the effect of LGR5 on multiple signalling
pathways, and the role of LGR5 homologues (Fig. 2).
Wnt-independent functions of Frizzled and LRP receptors
Given that the majority of human CRCs contain APC or β-catenin
mutations, and thus exhibit constitutive activation of the Wnt
signalling pathway downstream of the LRP/Frizzled receptors, one
might predict LGR5 modulation (and subsequent stability of Wnt
receptors) to have negligible effects upon the behaviour of
tumour cells. In reality, this now appears to be an overly simplistic
view. Recent evidence has demonstrated novel mechanisms of
Wnt signalosome regulation by APC, and alternative functions for
the Wnt receptors beyond Wnt signalling. Saito-Diaz et al recently
showed that inhibition of LRP6 (by siRNA and blocking antibodies)
was still able to reverse β-catenin signalling in APC mutant CRC
cell lines, or in cell lines where APC had been deleted.71 The
Alexander group have demonstrated that LRP5 controls glucose
uptake and its depletion suppresses the growth of both normal
breast and breast cancer cells (without affecting Wnt signalling).72
LRP6 has been shown to interact with PDGFβ and TGF-β receptor
1 at the cell membrane, where it serves as a co-receptor for
multiple ﬁbrogenic signalling pathways in pericytes and myoﬁ-
broblasts.73 Furthermore, Frizzled 6 has been reported to mediate
non-canonical/PCP Wnt pathways and JNK signalling in a variety
of developmental and malignant processes.74 Therefore, caution
must be taken with studies using LGR5 modulation on APCmutant
backgrounds, since the altered tumour cell behaviour may still be
a result of altered Wnt signalling or Wnt-independent functions of
Wnt receptors.
LGR5 regulation of other signalling pathways
The disparate behaviours of APC mutant CRC cells upon LGR5
modulation may be a consequence of the ability of LGR5 to
regulate multiple signal transduction cascades (in addition to Wnt
signalling). For example, LGR5 can also regulate Notch signalling in
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CRC cells. Hirsch et al reported downregulation of Notch signalling
components (including cleaved Notch1 and Sox6) upon
LGR5 silencing in SW480 cells, and elevated Notch signalling in
LGR5high SW480 spheres. Also in CRC cells, LGR5 has been reported
to interact and control the IQGAP1–Rac1 pathway.75 The authors
showed that LGR5 reduces phosphorylation of IQGAP1 at Ser-1441/
1443, thus increasing IQGAP1–Rac1 interaction and enhancing
cell–cell adhesion via actin cytoskeleton regulation. Stable knock-
down of LGR5 in APC mutant LoVo cells led to disorganisation of
the cytoskeletal structure and decreased cell adhesion, through
disruption of E-cadherin/β-catenin interaction.75 Outside of CRC,
LGR5 expression can impact upon MAPK signalling, which affects
the survival of neuroblastoma cells.76 LGR5−targeted siRNA
treatment of neuroblastoma cell lines resulted in a dramatic
reduction of phosphorylated MEK1/2 and ERK1/2, with an increase
in pro-apoptotic BimEL. Should LGR5 also regulate MEK/ERK
signalling in CRC cells, this could alter tumour behaviour
substantially, particularly during the stages of CRC development
where a KRAS mutation (which constitutively activates MAPK
signalling) has not yet been accrued. Finally, LGR5 has also been
shown to regulate Hedgehog77 and non-canonical Wnt signalling
pathways,78 both of which are active in colon cells.
Role of LGR5 homologues
The LGR5 homologues LGR4 and LGR6 are both capable of
binding and co-internalising with RSPO to potentiate Wnt
signalling.12,13 This has led to the hypothesis that functional
redundancy or compensatory mechanisms exist between the LGR
homologues. Could this explain the disparate roles for LGR5 in
CRC? LGR6 mutations have been reported in colon cancer;79
however, its expression is limited to a few tissues including hair
follicle stem cells,80 but not the intestine,81 suggesting a lack of
biological relevance in this context. LGR4 has an important
developmental role, as evidenced by the neonatal lethality of
LGR4-null embryos,82 and it is broadly expressed throughout the
intestinal crypt (not restricted to the crypt base stem cell positions
like LGR5).83 The lack of any overt intestinal phenotype upon
conditional deletion of LGR5 has led many to hypothesise that
LGR4 could compensate for LGR5 loss in the intestine.55
Furthermore, the ﬁnding that LGR5 overexpression can recover
the lost RSPO-induced β-catenin signalling induced upon LGR4
loss, has led to speculation that LGR4 and LGR5 have overlapping
functions.84 Like LGR5, LGR4 is also overexpressed in CRC, where it
is a poor prognostic indicator, an enhancer of Wnt/β-catenin
activity, and increases the invasiveness and metastatic potential of
CRC cells.85,86 None of the studies discussed above (See 'Plasticity
of LGR5+ cells in the normal gut and CRC’) have examined any
potential interplay between LGR4 and LGR5 in CRC. It would be
particularly interesting to see if the conclusions drawn from the
Melo or Shimokawa studies (replenishing of tumours by LGR5−
cells following LGR5+ cell ablation)21,69 would be affected by the
co-ablation of both LGR5+ and LGR4+ cells. Given these studies
indicating the alternative functions of the Wnt receptors
(controlled by LGR5), the regulation of multiple signalling path-
ways by LGR5, and functional compensation by LGR5 homo-
logues, it is thus challenging to assign a single pro-oncogenic or
tumour suppressive role for LGR5 in CRC.
TARGETING THE LGR5 PROTEIN FOR CRC TREATMENT
Assuming LGR5 does have an important role in CRC initiation and
progression, is the molecule even druggable? The protein satisﬁes
LGR5 overexpressed in CRC
LGR5 expression lost during CRC
progression
LGR5 predicts favourable prognosis
LGR5 overexpression inhibits
tumourigenicity
LGR5 knockdown promotes oncogenic
processes
LGR5 suppresses Wnt signalling
LGR5+ tumour cells are more clonogenic
LGR5 overexpression promotes
tumourigenicity
LGR5 predicts adverse prognosis
LGR5 knockdown inhibits oncogenic
processes
Normal gut homeostasis upon loss of
LGR5+ cells
LGR5+ cells interconvert with LGR5– cells
for drug resistance
APC deletion in LGR5– cells is tumourigenic
LGR5 expression has no prognostic value
LGR5 cells can sustain tumour growth
(LGR5+ cells required for metastatic
progression)
LGR5+ pool contains heterogeneous
subpopulations
Model 1–LGR5 as an oncogene in CRC
Model 2–LGR5 as a tumour suppressor in CRC
Model 3–Plasticity of LGR5 expression in CRC
Wnt-independent
functions of
Wnt receptors
Role of LGR5
homologues
LGR5 regulation of
multiple signalling
pathways
LGR5+ cell
LGR5– cell
LGR5
LGR5
Metastasis
Fig. 2 The complexity of LGR5 function in CRC. Model 1: LGR5 is overexpressed in CRC and plays an important role in CRC progression, where
it is associated with many oncogenic functions in CRC (in red) and predicts poor outcome. Model 2: Loss of LGR5 expression is important for
CRC progression because it performs multiple tumour suppressor roles (in green), suppresses Wnt signalling, and predicts favourable
outcome. Model 3: LGR5+ cells can freely interconvert with LGR5− cells to drive both oncogenic and normal processes in the gut (in blue). This
implies the LGR5 molecule has both important and redundant roles in CRC initiation and progression. A role for the LGR5 molecule in
metastasis is likely, given the requirement of LGR5+ cells for metastatic progression. LGR5 function in CRC is confounded by multiple variables
(in black).
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two highly desirable drug-design criteria: it is a GPCR, and it is
cell-surface expressed. Yet, despite structural characterisation of
LGR5 nearly 20 years ago, no speciﬁc pharmacological LGR5
inhibitors are commercially available. Junttila and colleagues
obtained encouraging results through the deployment of an
antibody-drug conjugate (ADC), involving an LGR5−targeted
antibody conjugated to the potent microtubule inhibitor mono-
methyl auristatin E (MMAE).87 LGR5-MMAE was effective at
reducing tumour size and proliferation in both xenografts and
APCminKRasG12D models of intestinal tumourigenesis, prolonging
the survival of mice with minimal toxicity in the relatively short
time period analysed (16 weeks). LGR5-MMAE also demonstrated
efﬁcacy within a primary human pancreatic cancer xenograft
model, providing hope that LGR5-targeted ADCs could be
adopted in other cancer types.
A study by the Sato group demonstrated some success by
combining a more acute targeting of LGR5 in organoids (using an
LGR5-iCaspase9 knock-in system) with widely used CRC clinical
agents, such as cetuximab (anti-EGFR antibody) and oxaliplatin
(platinum-based chemotherapeutic).21 Interestingly, cetuximab
in combination with LGR5 ablation exhibited the best synergy,
in agreement with our recent study that demonstrated increased
killing of human adenoma cells when LGR5 knockdown is
combined with geﬁtinib (EGFR inhibitor).51 However, in the Sato
study, tumour regression appeared to be dependent on the prior
ability of the agent to induce LGR5 mRNA expression (which
oxaliplatin did not), and CRISPR/Cas9-based therapies currently
remain some distance from the clinic.
It is important to note that, in light of recent data demonstrat-
ing that cancer and metastasis-driving LGR5+ cells can be freely
replenished from the LGR5–pool of a colon tumour,69 patients
would have long-term or even life-long dependence on LGR5-
targeted therapies. With this in mind, a thorough assessment
of the long-term treatment-associated toxicity of LGR5 targeting is
critical given the importance of LGR5 to normal colonic stem cell
biology, and the previously reported side effects (severe gut and
liver toxicity) of such strategies.61,87
Finally, if pharmacological targeting of LGR5 proves to be non-
viable, ineffective, too toxic, or expensive then perhaps other
avenues for LGR5 targeting in CRC treatment could be
pursued. There are a number of studies showing that dietary
factors such as high fat,88 curcumin,89 vitamin D,90 and alcohol,91
along with alterations to the gut microbiota,92 can affect both the
frequency and tumourigenicity of LGR5+ cells, and LGR5 expres-
sion level. Such approaches to modulate LGR5 expression in
tumour cells would be cost-effective if they could be proven to
reduce CRC incidence or promote tumour regression.
CONCLUSIONS
Studies examining the role of LGR5 in CRC have produced
disparate conclusions most likely arising from the breadth of
experimental models and systems used, and the intricacies of
LGR5’s function. The complexity of CRC tumours, driven by factors
such as tumour heterogeneity, tumour stage, cell of origin, stem
cell hierarchies and the microenvironment mean that LGR5
function is likely to vary considerably, depending on the context
in which it is assessed. Despite the controversy surrounding
the role of LGR5 in CRC, it would be hard to argue against an
important role for LGR5 at speciﬁc points during CRC develop-
ment or progression. In particular, there seems to be some
consensus on a role for LGR5 in the survival and/or metastatic
progression of CRC cells. Therefore, the timing of any LGR5-
directed therapy will be crucial for its long-term efﬁcacy, and
tumour stage-speciﬁc assessments of LGR5 therapies would be
useful within in vivo models of CRC metastases. This would
deﬁne where LGR5 targeting (individually or in combination
with current chemotherapeutics) is most effective, for example at
preventing/reverting metastatic conversion. This would circum-
vent the toxicities associated with long-term LGR5+ cell ablation
and identify a stage of human CRC development where LGR5
therapies could induce robust clinical remissions.
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